MicroTech Medical returns to profit in H1 FY26, net profit RMB 40.27 million; revenue rises 68.4% to RMB 414.14 million
PUBT · 1d ago
Share
Listen to the news
- MicroTech Medical posted revenue of RMB 414.14 million, up 68.4% year over year.
- Net profit swung to RMB 40.27 million from a loss a year earlier; basic EPS was RMB 0.10.
- Gross margin widened 6 percentage points to 57.7%.
- CGMS revenue more than doubled to RMB 313.02 million, driven by faster domestic and international sales.
- LinX S1 received EU CE marking in April 2026; second-generation patch insulin pump won China NMPA adult approval in July 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MicroTech Medical Hangzhou Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12294928), on August 21, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending